Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956692 · ClinicalTrials.gov registry record · Phase 3
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 531
- Enrollment target
- 20
- Study locations
NCT04956692 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 531 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04956692, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 531 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous and nonsquamous NSCLC by assessing the pharmacokinetics (PK), safety, and efficacy of pembrolizumab SC injection in combination with standard-of-care chemotherapy. The primary hypothesis of the study is Pembrolizumab SC is noninferior to pembrolizumab intravenous (IV) for Cycle 1 Area Under Curve (AUC) and Cycle 6 minimal concentration (Ctrough) at steady state. Participants who discontinue study treatment after receiving the first course of 35 administrations of pembrolizumab (approximately up to 2 years) for reasons other than disease progression or intolerability, may be eligible for a second course of pembrolizumab for up to approximately 1 additional year if they have experienced radiographic disease progression per RECIST 1.1 as assessed by BICR after stopping first course treatment.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Nab-Paclitaxel
- BIOLOGICAL Pembrolizumab SC
- BIOLOGICAL Pembrolizumab IV
Study Locations (20)
California
- St Joseph Heritage Healthcare-Oncology ( Site 0102) - Fullerton
- Cancer Blood and Specialty Clinic ( Site 0105) - Los Alamitos
- PIH Health Hematology Medical Oncology ( Site 0106) - Whittier
Florida
- Holy Cross Hospital ( Site 0017) - Fort Lauderdale
- Memorial Regional Hospital-Memorial Cancer Institute ( Site 0104) - Hollywood
- Advent Health ( Site 0013) - Orlando
Tennessee
- The University of Tennessee Medical Center ( Site 0050) - Knoxville
- Tennessee Oncology ( Site 0051) - Nashville
Texas
- Oncology Consultants, PA ( Site 0052) - Houston
- Millennium Physicians - Oncology ( Site 0097) - Houston
Arkansas
- St. Bernards Medical Center ( Site 0103) - Jonesboro
Indiana
- Fort Wayne Medical Oncology and Hematology ( Site 0101) - Fort Wayne
Kentucky
- Baptist Health Lexington ( Site 0099) - Lexington
Missouri
- St Luke's Hospital - Kansas City ( Site 0033) - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 531 participants |
| Start Date | 2021-08-05 |
| Est. Completion | 2026-10-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04956692
The ClinicalTrials.gov registry entry for NCT04956692 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 531 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (19% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT04956692 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04956692 about?
NCT04956692 is a clinical study titled "Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)". The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous and nonsquamous NSCLC by assessing the pharmacokinetics (PK), safety, and efficacy of pembrolizumab SC injection in combination with sta...
What is the current status of trial NCT04956692?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 531 participants. The study started on 2021-08-05. Estimated completion is 2026-10-14.
What conditions does trial NCT04956692 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT04956692?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Nab-Paclitaxel (DRUG), Pembrolizumab SC (BIOLOGICAL), Pembrolizumab IV (BIOLOGICAL).
Who is sponsoring clinical trial NCT04956692?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04956692 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.